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Abstract
The introduction of the genotype 2a isolate JFH1 was a major breakthrough in the field of hepatitis C virus (HCV), allowing
researchers to study the complete life cycle of the virus in cell culture. However, fully competent culture systems
encompassing the most therapeutically relevant HCV genotypes are still lacking, especially for the highly drug-resistant
genotype 1b. For most isolated HCV clones, efficient replication in cultured hepatoma cells requires the introduction of
replication-enhancing mutations. However, such mutations may interfere with viral assembly, as occurs in the case of the
genotype 1b isolate Con1. In this study, we show that a clinical serum carrying a genotype 1b virus with an exceptionally
high viral load was able to infect Huh7.5 cells. Similar to previous reports, inoculation of Huh7.5 cells by natural virus is very
inefficient compared to infection by cell culture HCV. A consensus sequence of a new genotype 1b HCV isolate was cloned
from the clinical serum (designated Barcelona HCV1), and then subjected to replication studies. This virus replicated poorly
in a transient fashion in Huh7.5 cells after electroporation with in vitro transcribed RNA. Nonetheless, approximately 3 weeks
post electroporation and thereafter, core protein-positive cells were detected by immunofluorescence. Surprisingly, small
amounts of core protein were also measurable in the supernatant of electroporated cells, suggesting that HCV particles
might be assembled and released. Our findings not only enhance the current method of cloning in vitro HCV replication-
competent isolates, but also offer valuable insights for the realization of fully competent culture systems for HCV.
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Introduction
Hepatitis C virus (HCV) is an enveloped positive-strand RNA
virus that belongs to the Flaviviridae family [1]. HCV infection is a
major cause of chronic hepatitis, and can lead to liver cirrhosis and
hepatocellular carcinoma in a significant percentage of infected
patients. Current interferon-a based therapy, in combination with
ribavirin, has limited efficacy and is often beset with side-effects
[2]. A better understanding of the virus life cycle could be helpful
for the development of new therapies, especially for the drug-
resistant genotype 1b.
Since hepatitis C virus was first identified in 1989 as the major
cause of non-A and non-B hepatitis [3], great progress has been
made, both in understanding the molecular basis of the virus and
in elucidating the distinct stages of its viral life cycle. Among the
milestones achieved in HCV research thus far are the heterologous
expression systems [4,5], the infection of the animal chimpanzee
model (Pan troglodytes) by HCV cDNA clones [6,7], the subgenomic
replicon system [8], the HCV pseudoparticle system (HCVpp)
[9,10], and finally those cell culture systems based on the JFH1
isolate, which facilitates comprehensive study of the viral life cycle
in vitro [11–14].
The HCV genome consists of the 59 non-translating region (59
NTR), a single open-reading frame encoding at least 10 proteins,
and the 39 NTR. The viral particle is composed of the structural
proteins, the core (C), and the envelope glycoproteins (E1 and E2).
The other non-structural proteins (NS proteins) include the
viroporin ion channel p7, the NS2-3 protease, the NS3 dual-
function protein (serine protease and helicase), the NS4A
polypeptide, the NS5A phosphoprotein, and the NS5B RNA-
dependent RNA polymerase (RdRp) [15]. Replication of HCV in
cultured human hepatoma cells remains an ongoing challenge to
researchers. The first autologous-replicating HCV molecules,
described in Lohmann et. al. [8], were based on the genotype 1b
isolate Con1 and required ‘‘replication-enhancing mutations’’
(REMs) within the NS proteins in order to increase RNA
replication to levels sufficient for experimental analyses [16].
Efficient replication of subgenomic replicons without the need for
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Full-length in vitro transcribed RNA of JFH1, if introduced to the
hepatoma cell line Huh7 via electroporation, leads to the
formation of a cell culture system that encompasses both the
extracellular and intracellular stages: translation of the RNA,
formation of replication complexes for the production of nascent
positive- and negative-strand RNAs, generation of new viral
particles and secretion, attachment of the new viral particles to
neighbouring cells and re-initiation of the cycle. Nevertheless,
(with one exception – the chimeric virus J6/JFH1 [11]), JFH1 and
all intra- and inter- genotypic chimeric viruses based on the JFH1
isolate require cell culture adaptive mutations that increase virus
titers without affecting replication [18–22].
Production of infectious genotype 1a HCV in cultured
hepatoma cells has also been described in the case of the H77
isolate containing 5 cell culture adaptive mutations (H77-S) [23].
Although this system overcame the genotype obstacle which had
plagued HCV cell culture systems, until recently it has found very
few applications. Persistent growth of a human plasma-derived
hepatitis C virus genotype 1b isolate in cell culture has also been
described. This system, however, is based on VeroE6 cells, which
contain a homozygous deletion of the IFN-a/b genes. Moreover,
HCV replication is enhanced by the adenovirus-associated RNAI
(VA-RNAI), thus rendering the system inappropriate for immune
studies that involve ongoing HCV infections [24].
Here, we exploited the ability of a HCV genotype 1b clinical
serum to infect the hepatoma cell line Huh7.5. For this purpose,
we used a serum sample with an exceptionally high viral load,
obtained from a patient with recurrent hepatitis C following liver
transplantation (LT). Viral RNA and HCV proteins were detected
4 days post inoculation and the infection occurred in a CD81-
dependent manner. In addition, we constructed a consensus full-
length HCV cDNA clone from this serum, designated Barcelona
HCV1 (BHCV1), and carried out in vitro replication studies in
Huh7.5 cells. Finally, in further analyses we generated an inter-
genotypic chimeric virus between BHCV1 and JFH1.
Results
Inoculation of Huh7.5 cells by a clinical serum
A clinical serum was prepared based on a sample provided by a
chronic HCV patient who had undergone LT and who presented
severe and recurrent hepatitis with an exceptionally high viral load
(for detailed information see the Materials and Methods section). We
chose the ‘‘cured’’ Huh7 replicon cell clone designated Huh7.5
[25] for our replication and infection studies due to its ability to
support high levels of replication and also because it expresses
sufficient levels of diverse HCV receptors on the surface [26].
Initially, Huh7.5 cells were inoculated with the patient serum;
additionally, as a negative control, cells were inoculated with a
control HCV negative serum. As a reference for our inoculations
we used the following cell cultured prepared viruses (HCVcc): J6/
JFH1 as a positive control and supernatant from cells electropo-
rated with a replication-deficient form of the JFH1 isolate (JFH1/
DGDD) as a negative control. HCV RNA extracted from
inoculated cells was analyzed by specific quantitative reverse-
transcription PCR (qRT-PCR). Analysis was conducted in a time-
course fashion in order to better understand the HCV replication.
As shown in Fig. 1A, 4 h post inoculation with patient serum,
HCV RNA detection was as efficient as that achieved with
infection by J6/JFH1 HCVcc inoculation. However, these serum
viruses presented much lower replication capacities in Huh7.5 cells
than did the J6/JFH1 viruses based on the replication curve
calculated at 96 h post inoculation. In addition, we performed
neutralization studies with a well-characterized a-CD81 receptor
antibody. To this end, cells were incubated with either the
neutralizing a-CD81 antibody JS-81 or mock incubated, one hour
prior to inoculation. Afterwards, cells were inoculated with diverse
viruses. Analysis of HCV RNA was performed 96 h post
inoculation. As shown in Fig. 1B, both infections of Huh7.5 cells
– that by J6/JFH1 and that by serum viruses – were effective and
were neutralized by a-CD81 antibodies. Nevertheless, infection
with the patient serum was much less efficient than that recorded
with the J6/JFH1 infection, as was similarly observed in the
replication-kinetic experiment (Fig. 1A); in the case of the J6/JFH1
virus an MOI 0.2 TCID50/mL was used, whereas the MOI for the
serum infection was 100 IU/mL. However, the distinct MOI
estimation methods used for HCVcc and the serum-derived virus
could have caused a discrepancy since the COBAS Taq-Man
HCV Test cannot discriminate between functional and non-
functional HCV particles and free serum HCV RNA. Our efforts
to eliminate background HCV RNA measurements below ,10
3
molecules/25 ng total RNA were unsuccessful, probably due to
traces of genomic DNA still present in the final sample
preparation.
To further corroborate our findings, we performed immuno-
fluorescence (IF) staining of core protein in inoculated cells
(Fig. 1C). Core-positive cells for J6/JFH1-infected cells were
detectable as early as 24 h post infection, whereas core-positive
cells for serum-inoculated cells were present from 72 h post
inoculation and thereafter. IF staining 96 h post inoculation was
substantially more intense in the J6/JFH1-infected cells. Most
likely, the less intense core signals detected in serum-inoculated
cells reflect of lower RNA replication, as deduced by the qRT-
PCR data, than of the antigenic differences inherent in the a-core
antibodies and of the distinct half-life periods found in the core
molecules.
HCV cDNA consensus clone isolated from patient serum
A full-length consensus HCV cDNA was drawn from the serum
by cloning the 59 NTR with a 59/39 RACE commercial kit and the
full open-reading frame with 5 overlapping PCRs (see Supporting
Information). The full-length clone genotype 1b was completed by
adding the 39 NTR of the genotype 1a H77 isolate (Fig. 2A). The
addition of a heterologous 39 NTR fulfilled the prerequisite for a
kissing-loop interaction between the stem loop 5BSL3.2 at the
NS5B-coding region and the stem loop X-tailSL2 at the X-tail of
the 39 NTR as described in Friebe et. al. [27] (data not shown).
This new isolate, designated Barcelona HCV1 (BHCV1), possesses
a 9591 nt genome. BHCV1 also contains a long open-reading
frame spanning nt 342–9377, and codes 3012 amino acids (aa).
The well-characterized genotype 1b isolates Con1 [8] and CG1b
[28] encode only 3010 aa. Compared to Con1 and CG1b,
BHCV1 isolate contains two extra amino acids in the inter-
genotypic variable region of E2 (IgVR), as does JFH1 isolate.
Figure 2B represents a neighbor-joining phylogenetic tree
composed of BHCV1 and other known HCV isolates of various
genotypes. The tree was created with the Tamura-Nei model [29]
and the exclusion of the 39 NTRs of all isolates was accounted for.
The full-length sequence of the BHCV1 isolate has been submitted
to the GenBank database under accession number HQ719473.
Replication studies
In order to perform replication studies with the new cloned
BHCV1 isolate, we designed a subgenomic replicon construct
carrying the firefly luciferase gene as a reporter (Luc-SGR-BHCV1).
Translation of the firefly gene occurs under the HCV internal
ribosomal entry site (IRES, nt 1–389), and is followed by the
HCV Genotype 1b Replication in Cell Culture
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(Fig. 2A). The latter drives the expression of HCV proteins NS3-
NS5B, similar to previously described subgenomic replicons [8]. A
negative control construct was cloned by deleting the NS5B GDD
motif responsible for RNA replication (DGDD). These constructs,
as well as the full-length BHCV1 construct and its DGDD negative
control, were cloned into puC vectors downstream of a T7
promoter for the production of in vitro RNA transcripts.
Huh7.5 cells were electroporated with RNA from subgenomic
replicons of BHCV1, the DGDD acting as a negative control, or
with equivalent constructs of the JFH1 isolate serving as
references. Post electroporation luciferase activity was measured
both in a short-term (4 h to 4 d) and in a mid-term fashion (up to
21 d post electroporation), in which cells were passed 3 times (on
days 4, 9, 15). As shown in Fig. 3A, significant amounts of
luciferase activity can be measured only in cells transfected with
the JFH1 construct and then only in a transient fashion. Cells
transfected with the Luc-SGR-BHCV1 RNA did not express
significant differences in luciferase activity compared to those cells
transfected with both negative DGDD controls, which suggests
that this construct underwent little or no replication.
Huh7.5 cells harboring the subgenomic JFH1 replicon typically
undergo a period of cell crisis, beginning just a few days post
electroporation, most likely due to the high replication capacity of
this isolate [14,21]. In our studies, Huh7.5 cells electroporated
with subgenomic replicons also entered such a crisis phase
approximately 9 days post electroporation. JFH1 subgenomic
replicons failed to replicate in Huh7.5 either during or after cell
crisis (Fig. 3A). In contrast, Huh7.5 cells electroporated with the
subgenomic replicons of the BHCV1 isolate did not present any
crisis markers or signs of toxicity (data not shown).
In an attempt to obtain a better image of BHCV1 isolate
replication, we electroporated Huh7.5cellswithin vitro transcripts of
full-length virus. Similar to those replication studies involving
subgenomic replication constructs, we included a DGDD as a
negative control and JFH1 constructs as references. RNA
replication in the electroporated cells was monitored by quantitative
reverse-transcriptase PCR (qRT-PCR), with conserved primers
binding at the 59 NTRs of both isolates (BHCV1 and JFH1). As
shown in Fig. 3B, apart from the cells electroporated with JFH1
RNA, in all other cells the HCV RNA gradually decayed during the
experiment. The presence of HCV RNA molecules above the cut-
off point specified by this method (,10
3 molecules/25 ng total
cellular RNA) up to 21 days post electroporation can be likened to a
slow degradation of the input HCV RNA rather than an active
replication of these constructs. Additionally, the JFH1 virus
replicated in cells both during and after the cell crisis period, in
contrast to the subgenomic replicon, albeit at low levels.Finally, two
weeks post electroporationand after 2 cell passages, we detected low
amounts of HCV RNA molecules in those cells electroporated with
full-length BHCV1 RNA, although still to a significantly higher
degree than was the case with the negative controls. This was
additionally confirmed for the 21 d post electroporation time-point,
which suggests that replication of this virus was attenuated.
To further corroborate our results, we not only performed
Western blot analysis of intracellular core expression in electro-
Figure 1. HCV RNA and core protein detection in Huh7.5-inoculated cells. (A and B) HCV RNA was analyzed by qRT-PCR analysis at the
indicated time points (A) or at 96 h post inoculation (B). Results represent the mean values from duplicate wells, measured in triplicate, from a
representative experiment of 3 (mean 6 SD; n=6). (C) Cells were stained with a-core specific antibodies (clone C7-50) and a-mouse Alexa-568
antibodies (red). Cell nuclei were counterstained with DAPI (blue), magnification 1006.
doi:10.1371/journal.pone.0023587.g001
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in the supernatant of the cell cultures (Fig. 4A). As shown in
Fig. 3C, transient intracellular core expression was detected in cells
transfected with the JFH1 RNA. Core expression decreased at
days 9, 15 and 21 post electroporation due to the loss of replication
potency. For the BHCV1 construct, an intracellular core was
detected as early as 4 to 24 h post electroporation, reflecting the
input RNA translation. No core proteins were detected in cell
extracts at the remaining time points of the experiment, detections
of which continued until 21 d post electroporation.
As shown in Figure 4A, we measured the extracellular core
using a core ELISA at these particular time points. Huh7.5 cells
transfected with JFH1 RNA presented a significant degree of core
release (,10
4 fmol/L) at 4 days post electroporation. For all other
constructs, including the negative DGDD controls, core release
was minimal, measuring very close to the cut-off level we set
(20 fmol/L) based on our experience with the commercial core
ELISA kit. These small amounts of core protein most likely
stemmed from the input RNA expression, as was clearly
demonstrated by the Western blot analysis. Interestingly, at 24 h
post electroporation core levels in the supernatant of the BHCV1-
electroporated cells were not elevated, as was the case with the
low-replicating Con1 isolate [8], which suggests that some
impairment in particle production occurs within the first hours
Figure 2. Presentation of the Barcelona HCV isolate 1. (A) Genetic structure of the isolate Barcelona HCV1 (BHCV1), the subgenomic variant (Luc-
SGR) withfirefly luciferasereporter gene(Luc)andthenegative control viruseswith a GDD deletion(DGDD) atthe NS5B region(EI: Encephalomyocarditis
virus). (B) A phylogenetic tree drawn of the BHCV1 isolate including strains of various genotypes (39 NTRs were excluded from this analysis). JFH1
accessionnumberis AB047639;HC-J6CH isD00944;VAT96isAB031663;ED43 isGU814265; H77 isAF009606;1804 is AM910652;Con1is AJ238799;HCV-
J is D90208; HCVT212 is AB049099; HCV-N is S62220; HCV-BK is M58335; VN235 is D84263; Th580 is D84262; VN405 is D84264, CB is AF046866;
JPUT971017 is AB030907 and NZL1 is D17763; The length of the horizontal bar indicates the number of nucleotide substitutions per site.
doi:10.1371/journal.pone.0023587.g002
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protein could be detected in the supernatant of BHCV1-
electroporated cells beginning at 15 d post electroporation. This
is in contrast to the core protein levels detected in those cells
electroporated with the DGDD constructs, which fell below the
cut-off level. The latter observation is consistent with the low
amount of intracellular RNA detected in BHCV1-electroporated
cells 15 d post electroporation and thereafter.
Taken together, we believe that the replication capacity of the
BHCV1 isolate remains very low during the first 3 weeks following
electroporation of Huh7.5cells. In fact, itcannotbedetected either by
intracellular HCV protein analysis or by use of subgenomic replicons
carrying luciferase reporters. Only very specific and accurate
methods, such as qRT-PCR or core ELISA analysis, enabled us to
detect low amounts of RNA molecules or core antigen, respectively.
Cell passages
Based on our previous results, we tried to adapt the BHCV1
virus in cell culture. To this end, Huh7.5 cells electroporated with
BHCV1 virus were passaged up to 12 times. Extracellular core
secretion was monitored by core ELISA (Fig. 4B). BHCV1
replication was monitored indirectly by IF analysis of core
expression intracellularly, at different cells passages (Fig. 4C). As
shown in Fig. 4B, the low core secretion levels presented in
passages 1–4 fell below the cut-off limit of the core ELISA for
passages 5–6. Nevertheless, starting at passage 7, core secretions to
the supernatant elapsed, reaching maximum levels (up to
250 fmol/L) by passage 8. After this time point, core secretions
began to decline, although they remained quite detectable. In
similar fashion, intracellular core expression peaked around
passage 8, with core-positive cells constituting at least 20% of
the total cell population (Fig. 4C). Nonetheless, intracellular core
expression levels, as well as extracellular core secretion, remained
low compared to that produced by the JFH1 isolate.
To firmly demonstrate the presence of core protein expression
within passaged cells, we conducted a detailed immunofluores-
cence analysis of 1) the core protein expressed in BHCV1-
transfected cells at the higher passages and of 2) that expressed in
Huh7.5 cells following RNA electroporation of the JFH1 isolate.
Core protein within infected and JFH1-electroporated cells
Figure 3. Replication studies of the BHCV1 isolate. (A) Luciferase activity in the electroporated cells with the sugbenomic RNAs in both transient
(4 h–4 d) and mid-term fashions (4 d–21 d). (B) HCV RNA in the electroporated cells at similar time points as determined by quantitative reverse-
transcription real-time PCR (qRT-PCR). For A and B, data represent the mean values from duplicate wells, each measured in triplicate, from a representative
experiment of 3 (mean 6 SD; n=6). (C) Western blot analysis of core protein in electroporated cells with full-length RNAs expressed intracellularly in short-
term (4–96 h) and mid-term fashions (9–21 d). Positive and negative control cell lysates were obtained from Huh7.5 cells transfected with a core protein
expression plasmid under the control of the CMV promoter (pcDNA3.1/Core) or an empty plasmid (pcDNA3.1), respectively.
doi:10.1371/journal.pone.0023587.g003
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nascent viral particles is believed to take place [30]. We were able
to show a clear co-localization of core protein expression with LDs
in BHCV1-passaged cells, similar to that observed in JFH1-
electroporated cells, although core levels were lower (Fig. 5, panels
V–VIII). To further corroborate our findings with a virus that
expresses high amounts of BHCV1 core protein, we performed the
same IF analysis in Huh7.5 cells electroporated with the RNA of a
BHCV1/JFH1 intergenotypic chimeric virus (described in detail
in the next subsection). Most of the core protein expression within
these electroporated cells was also found to surround the LDs
(Fig. 5, panels I–IV).
Since it is known that HCV in cell culture accumulates cell
culture adaptive mutations, resulting in either replication-enhanc-
ing mutations [16] or in adaptive mutations that have no effect on
replication but that increase virus production or infectivity
[18,19,21,22], we sought to extract BHCV1 RNA from passaged
cells and sequence the entire genome. To this end, total RNA was
prepared from BHCV1 Huh7.5-electroporated cells (passage 10)
and by employing the same strategy used for cloning the BHCV1
isolate from patient serum, we amplified the passaged BHCV1
genome. This confirmed the existence of the BHCV1 genome in
the passaged cells since re-amplification of the genome from total
RNA cell extract was possible. Surprisingly, we mapped only one
adaptive mutation in the E2 region (V632I at the amino acid level,
GTCRATC at the nucleotide level), suggesting that the BHCV1
isolate does not accumulate adaptive mutations in cell culture.
BHCV1/JFH1 intergenotypic chimeric virus
To further characterize the BHCV1 isolate, we created a
BHCV1/JFH1 intergenotypic chimeric virus and subjected it to
replication and infection studies (Fig. 6A). Just as inter-genotypic
JFH1 chimeric viruses have been conclusively shown to produce
low levels of infectious particles [20], so too the BHCV1/JFH1
chimera did produce infectious particles, albeit at low levels (,10
2
TCID50/mL), specifically at 4 days post Huh7.5 cell electropora-
tion with in vitro RNA transcripts. These cells (passage 0) were
passaged, with cell culture supernatant being tested each time for
Figure 4. Core protein production during cell passages. (A) Core protein measured in the supernatant of JFH1- or BHCV1-electroporated
Huh7.5 cells, and the equivalent DGDD negative controls, both in short-term and mid-term fashions. (B) Core protein released in the supernatant
from BHCV1 electroporated cells at different passages (C) Intracellular core expression at different passages as detected by core protein IF. Cells were
stained with a-core specific antibodies (clone C7-50) and a-mouse Alexa-568 antibodies (red). Cell nuclei were counterstained with DAPI (blue),
magnification 1006.
doi:10.1371/journal.pone.0023587.g004
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Fig. 6C, at each passage, up to passage 8, cell culture supernatants
contained higher amounts of infectious virus, reaching infectivity
titers similar to those observed with the high-virus-productive J6/
JFH1 chimera (,10
5 TCID50/mL), suggesting that the chimera
BHCV1/JFH1 is prone to cell culture adaptation. We additionally
verified this finding with a-core IF analysis comparing an
enhanced virus spread of the adapted virus with the initial
chimera (data not shown).
Total RNA from Huh7.5 cells (passage 8) was extracted, cDNA
was prepared, and then both parts of the virus, the BHCV1 and
the JFH1, were cloned and sequenced. In the case of BHCV1, we
mapped one adaptive mutation in the E1 region (C307R) and ten
adaptive mutations at the E2 gene: N411D, S467A, A476N,
P478S, S479H, D480S, L481S, Q493R, S523F, and T529S
(Table 1). Five of these adaptive mutations (positions 476, 478,
479, 480, and 481) were located within the hypervariable region 2
(HVR2) [31], which has been postulated to play a role in the
binding of various cell-surface receptors [32]. For the JFH1 part,
we identified 1 adaptive mutation at the viral protease NS2
(G899E), 2 at the NS4B protein (E1874Q, V1896G) and 5 at the
NS5A phosphoprotein (E2369K, E2383K, D2399N, E2408K,
and L2438V). The NS2 amino acid G899 is located at position 88,
which is at the end of the protease’s third putative transmembrane
domain. Changing glycine to leucine at this position had a rather
moderate inhibitory effect on particle production in the J6/JFH1
chimeric virus [33]. The two mutations identified at the NS4B
protein are of special interest since both appeared at very well-
conserved amino acid positions. Furthermore, the first 4 mutations
found in the NS5A region were clustered in domain III of the
molecule, which plays an essential role in HCV particle assembly
[34]. Finally, in order to enhance viral assembly and release, we
initially introduced the V2440L adaptive mutation at the C
terminal domain of NS5A, which improved viral production in the
Con1/JFH1 chimeric virus [21]. To our surprise, this mutation
reverted to wild-type (L2438V).
Figure 5. Core protein subcellular localization on LDs. Huh7.5 cells were electroporated with BHCV1/JFH1 (panels I to IV), JFH1 (panels IX to
XII), JFH1/DGDD (panels XIII to XVI) and fixed 72 h post electroporation. Panels V to VIII represent fixed cells of BHCV1 transfected cells at passage 9.
Fixed cells were analyzed for the subcellular localization patterns of core protein (red) by immunofluorescence, whereas LDs were stained with
BODIPY493/503 (green). Cell nuclei were counterstained with DAPI (blue), magnification 1006.
doi:10.1371/journal.pone.0023587.g005
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In order to clarify what role(s) the adaptive mutations in
glycoprotein regions may play in the adaption process of the
BHCV1 isolate and its chimera with the JFH1 isolate, we
generated wild-type and mutated HCV pseudoparticles (HCVpp)
for the BHCV1 isolate as follows, with relevant results noted: i.
HCVpp bearing the wt E1E2 proteins and, as an infectious
control, wt E1E2 from the genotype 1b isolate CG1b [28]; ii.
HCVpp harboring E1E2 glycoproteins with the adaptive mutation
V632I on their surface appeared in the passaged BHCV1; iii.
HCVpp harboring the Q493R mutation; iv. HCVpp harboring all
five adapted mutations appeared at the HVR2 region (HVR2 mut)
of the chimeric BHCV1/JFH1 virus; and finally, v. HCVpp with
the adaptive mutation appeared in the E1 glycoprotein (C307R).
Infection studies with the pseudoparticles revealed a 2- to 3-fold
enhancement in HCVpp infectivity in those harboring the
adaptive mutations versus their wt counterparts (Fig. 7), with the
exception of the adaptive mutation C307R. Further reverse-
genetic studies should be carried out in order to determine the
role(s) played by the other adaptive mutations in entry process of
the BHCV1 isolate.
Discussion
In this study we exploited the potential capacity of a natural
HCV virus, present in the serum of a chronically infected patient
who had undergone LT, to infect Huh7.5 cells in vitro and
successfully replicate within these cells. Studies examining HCV
kinetics, both during and immediately following LT, have shown
that although a rapid drop in HCV viral load occurs during the
initial hours after liver graft reperfusion, the viral load then
increases as early as 12 h after graft reperfusion. In a significant
portion of HCV patients who undergo LT, pre-transplantation
levels are surpassed within 1 to 3 months [35]. Here, we used a
serum harvested 3 months post LT from a patient with aggressive
and recurrent hepatitis C following surgery, and whose condition
was characterized as acute cholestatic hepatitis. Both innate and
adaptive immunity play important roles in the control of HCV
infection. In the transplant setting, however, any anti-HCV
response takes place (in most cases) in the context of a non-self
histocompatibility complex, in conjunction with severe immuno-
supression [36]. Revie D. et. al., have reported the transmission of
patient-derived HCV in secondary cells (e.g., macrophages, T-cells
and B-cells) during long-term cell culture [37]. According to their
findings, only patient sera that contain high levels of HCV RNA
have sufficient infectious virions to ensure successful transmission
of HCV in vitro. Therefore, we concluded that our particular
serum, with its extraordinary high viral load, is of high value.
Since the discovery of HCV in 1989, researchers have tried to
inoculate cells in vitro using infectious HCV isolated from HCV-
positive patients. These efforts included not only several types of
liver cells, but also cells of non-liver origin, such as HeLa, CEM,
H9, Jurkat, Molt 3, Molt 4, U937, P3HR1, Raji, and Daudi cells
[38]. Unfortunately, the results of these studies, in particular the
sustained replication of HCV, remained irreproducible until the
JFH1 isolate-based HCVcc system and the highly permissive
replication clone Huh7.5 were described [11,13,14]. Here, we
report that inoculation of Huh7.5 with natural virus causes
productive infection, which can then be neutralized by a-CD81
antibodies. Nevertheless, such an infection proved much less
efficient than that involving cell culture-produced recombinant
HCV virus. Moreover, the natural virus contains a wide variety of
Figure 6. Infectivity of the BHCV1/JFH1 chimeric virus. (A) Genetic structure of the BHCV1/JFH1 chimeric virus. Structural proteins, p7, and the
first transmembrane domain of NS2 of the isolate BHCV1 (amino acids 1–844) were fused in-frame to the remaining non-structural proteins of the
JFH1 isolate. Both NTRs are of JFH1 origin. (B) Schematic presentation of the experimental plan for the cell culture adaptation of the BHCV1/JFH1
chimeric virus. (C) qRT-PCR analysis of naı ¨ve Huh7.5 cells inoculated with supernatant derived from Huh7.5 cells containing the BCHV1/JFH1 virus
from different passages. J6/JFH1 infection: MOI 0.2 TCID50/mL. Data are expressed as the mean of duplicate infections measured in triplicate (mean 6
SD; n=6). # Estimated infectivity ,10
2 TCID50/mL; { Estimated infectivity ,10
5 TCID50/mL.
doi:10.1371/journal.pone.0023587.g006
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creating a heterogeneity that greatly hindered further experimen-
tal analyses; e.g., entry studies examining various E2 hypervariable
regions, etc.
A consensus genotype 1b HCV cDNA clone was reconstructed
from patient serum and designated Barcelona HCV1 (BHCV1).
Our replication studies with the firefly luciferase gene revealed that
only the JFH1 genome boasted a high replication capacity, albeit in
a transient fashion. Due to the poor and transient replication of the
Luc-SGR-BHCV1 construct, we undertook similar efforts with
those sub-genomic replicons that carry a neomycin-resistant selective
marker (Neo-SGR-BHCV1), similar to that described by Lohn-
mann et. al [8]. Unfortunately, we were unable to obtain any
neomycin-resistant colonies after 21 days of selection with the
antibiotic (data not shown), suggesting that this Neo-SGR-BHCV1
construct failed to accumulate any cell culture adaptive mutations.
We therefore concluded that although subgenomic replicons have
proven to be valuable tools for replications analyses of numerous
flaviviruses and could contain various well-tolerated heterologous
elements (gene reporters, heterologous IRES etc), comprehensive
imaging of a flavivirus’ replication capacity can only be obtained
with studies that utilize wild-type isolates. Indeed, when Huh7.5
cells entered the ‘‘cell crisis’’ phase, we failed to detect any luciferase
activity in the subgenomic replicon, whereas we were able to
measure JFH1 replication for the wild-type virus using qRT-PCR.
These data suggest that only extremely precise techniques are
suitable for measuring the replication capacity of viruses that
replicate at low levels, especially for such isolates as BHCV1.
Since replication studies with subgenomic replicons revealed
that the BHCV1 isolate had a low in vitro replication capacity, we
exploited its potential capacity for adaptation by passaging
electroporated Huh7.5 cells. As shown in Fig. 4B, core secretions
in the supernatant of electroporated cells remained low for the first
6 passages. However, beginning with passage 7 and for 5 passages
thereafter, Huh7.5 cells produced sizeable amounts of core
secretions, suggesting the presence of particles in the supernatant
of the passaged cells. Intracellular core analysis by IF confirmed
the presence of core secretions within the passaged cells, which
indicated that the BHCV1 isolate now had an increased
replication capacity, thus facilitating the ready detection of core
protein, both intracellularly and extracellularly. Finally, higher
magnification of core-stained cells at passage 9 showed the
characteristic circular fluorescence staining around the lipid
droplets [30], thus strengthening our hypothesis that the BHCV1
isolate was successfully replicating within these cells. Total RNA
was extracted from these cells and then the BHCV1 isolate was
amplified, confirming its presence therein. In attempting to
sequence this passaged version and to map these cell culture-
adapted mutations, we failed to identify any mutations except that
located at the E2 region.
These are very important findings for two reasons: First, these
results support the hypothesis that a consensus HCV genome can
be maintained in passaged cells, although replication capacity does
become attenuated. Second, this genome accumulated neither
replication-enhancing mutations, which could have been delete-
rious for particle production as was the case with Con1, nor cell
culture-adaptive mutations that might enhance virus production.
Therefore, we would suggest that there exist qualitative differences
in the manner in which this consensus genome replicates in cell
culture that might better reflect the in vivo setting.
When we extended our analysis, by creating a BHCV1/JFH1
chimeric intergenotypic virus, we uncovered the expected adapted
Table 1. Amino acids substitutions identified in adapted
viruses.
Virus
Substitution
frequency
a
Amino acid
substitution
b Protein
BHCV1 4/4 V632I E2
BHCV1/JFH1 4/4 C307R E1
4/4 N411D E2
4/4 S467A E2
4/4 A476N E2
4/4 P478S E2
4/4 S479H E2
4/4 D480S E2
4/4 L481S E2
4/4 Q493R E2
4/4 S523F E2
4/4 T529S E2
2/4 G899E NS2
4/4 E1874Q NS4B
2/4 V1896G NS4B
1/4 E2369K NS5A
4/4 E2383K NS5A
4/4 D2399N NS5A
4/4 E2408K NS5A
4/4 L2438V NS5A
aFrequency of amino acids substitution identified in cloned PCR products.
bNumbers refer to amino acid positions of each respective virus.
doi:10.1371/journal.pone.0023587.t001
Figure 7. Adaptive mutations enhance infectivity of HCVpp.
Infectivity of HCVpp from the BHCV1 isolate harboring adaptive
mutations on their surface is indicated; numbers of the amino acids
refer to positions at the BHCV1 isolate; ‘‘HVR2 mut.’’ contains 5 mutations
clustered at the hypervariable region 2 of the E2 glycoprotein. HCVpp
harboring on their surface E1E2 glycoproteins of the CG1b isolate were
used as an infectivity control. Infections by pseudoparticles produced
without envelope glycoproteins ‘‘No ENV’’ were used as an unspecific
infectivity control. Results show a representative experiment of 3. The
infectivity is expressed as the mean of fold induction relative to the
infectivity obtained from HCV pseudoparticles harboring the wild-type
BHCV1 E1E2 glycoproteins. Infections were carried out in duplicate and
measured in triplicate (mean 6 SD; n=6).
doi:10.1371/journal.pone.0023587.g007
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observed with the chimera J6/JFH1, was also accompanied by
adaptive mutations clustered together in the glycoprotein regions.
Using reverse genetics, we analyzed the impact of these adaptive
mutations on the entry of the BHCV1 isolate, which we
accomplished by generating wild-type HCVpp of this particular
isolate as well as that HCVpp harboring the adaptive mutations.
One of these mutations was mapped to the E1 glycoprotein on a
cysteine residue, which is critical for the secondary structure for
this glycoprotein. The infection capacity of those HCVpp
harboring only this mutation was significantly downgraded due
to a loss in stabilization of the covalent complexes formed in
association with E2, which are stabilized by disulphide bonds [39].
Further analyses of this mutation, in combination with the other
adaptive mutations, should be carried out in order to clarify the
role of this particular amino acid change.
As five of the adaptive mutations that arose in the BHCV1/
JFH1 chimeric virus appeared in a row clustered along the HVR2
region of the E2 glycoprotein (P478S, S479H, D480S, and
L481S), we therefore analyzed all of these mutations in one single
mutant HCVpp. As shown in Fig. 7, HCVpp harboring these
mutations presented a 3-fold greater infectivity level compared
with their wt counterparts. Additionally, we examined the single-
point mutation Q493R after observing a turn from a non-polar
(glutamine) to a polar amino acid (arginine) arrangement. HCVpp
harboring this mutation were 2-fold more infectious than the wt
pseudoparticles. Finally, we examined the single mutation that had
appeared in the BHCV1 full-length isolate (V632I) and similarly
found a 2-fold increase in infectivity in the HCVpp system.
Mutations that arose in the JFH1 part of the BHCV1/JFH1 are
of special interest: First, because several conserved amino acids had
undergone mutations (i.e., V1896G). Second, due to these amino
acids changes, the physicochemical properties of the relevant
protein domains most likely changed as well. For example, the
G899ofNS2,whichisa non-polaramino acid andwhich,according
to the NS2 3D structure model, forms part of the third
transmembrane domain of NS2 [33], changed to the polar amino
acid E. Additionally, 3 polar E of the domain III of NS5A, which
hasanegativeside-chain charge,changedtopolarKand had a high
positive side-chain charge, confirming the essential role it plays in
thisregioninterms ofvirionproduction and assembly.Toattempt a
reverse-genetics transformation of these NS adaptive mutations
back to the wild-type virus remains well beyond the scope of this
study. Besides, adaptation of the JFH1 virus in cell culture demands
considerable flexibility, since each individual adaptation can lead to
different adaptive mutations [21], though all with the same result:
an increase in particle production and release.
Although in vivo infectivity has thus far been conclusively shown
for several consensus HCV isolates, including those of genotype
1b, the production of infectious particles in transfected Huh7 cells,
or in their derivatives, has remained problematic because of the
low replication rates of these isolates. However, replication-
enhancing mutations are not the solution, at least not for the
genotype 1b isolate Con1, since such mutations cause impairments
in particle production [15]. As shown in this study, the BHCV1
isolate not only maintained the low replication capacity of other
consensus isolates, but following several cell passages it increased
core (and most likely others) protein expression, both intracellu-
larly and extracellularly. Although there is still no formal proof
demonstrating that this core protein corresponds to the virus
particles, our data suggest that HCV particle assembly has
occurred. The various methods of replication enhancement, such
as the treatment of transfected cells with kinase inhibitors or with
vitamin B6, may improve this in vitro HCV cell culture system and
thereby provide a favorable tool for both in vitro study of the virus
and screening of anti-viral drugs.
In summary, we demonstrate that inoculation of Huh7.5 cells
with the serum of an HCV-infected patient can facilitate core and
RNA detection of HCV in inoculated cells. Although patient sera
are an abundant source of HCV, it is of limited use in vitro, most
likely due to the quasi-species nature of the virus and because of the
low replication capacities of natural viruses in Huh7.5 cells. Thus,
the cloning of recombinant HCV isolates could offer one solution
for the in vitro propagation of the virus. As with many other
recombinant consensus isolates the BHCV1 virus replicated poorly
in cell culture. Nevertheless, following several cell passages post
electroporation and without the aid of replication-enhancing
mutations, both BHCV1 core protein-positive cells and core
secretion in the supernatant could be detected, which suggests that
the machinery of replication and protein production had been
enhanced. We believe that HCV isolates with low replication
profiles are tolerated at low states of replication within Huh7.5 cells.
The realization that such HCV isolates could enhance their
replication capability after a certain point, without the need of
replication-enhancing mutations,maynot only provide newinsights
into the workings of current and future HCV isolates, but may also
finally give rise to new in vitro replication-competent isolates.
Materials and Methods
Ethics statement
The Investigation and Ethics Committee of Hospital Clinic
Barcelona approved our protocol, which conformed to the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from the patient included in this study.
Patient profile
HCV positive serum was obtained from a 65-year-old chronic
female patient who had undergone LT because of HCV-related
cirrhosis. The HCV genotype was 1b, which was determined by
restriction fragment-length polymorphism analysis of the 59 NTR of
the HCV genome, as previously described [40]. Following LT, the
patient developed acute cholestatic hepatitis; three months after LT the
patient reached a bilirubin peak of 19 mg/dl and an ALT of 500 IU/
mL. At this point her viral load reached an extraordinary high viral
level: .10
9 IU/mL, as deduced by real-time PCR (COBAS Taq-Man
HCV Test, Roche Diagnostics, Mannheim, Germany) and it was
therefore decided to use this serum for our experimental analyses.
Antiviral treatment was started at the usual dose (pegylated interferon
alpha 2b 1.5 mg/kg/week and ribavirin 1000 mg/d). A rapid decrease
in ALT and bilirubin levels was observed and the viral load reached
SVR. In December 2009 the SVR was confirmed; specifically, the viral
load fell below the detection limit (,25 IU/mL), remaining at this level
even during manuscript preparation.
Cell culture and cell lines
Huh7.5 and 293T cells were grown in Dulbecco’s modified
Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented
with 2 mM L-glutamine, non-essential amino acids, 100 U of
penicillin per ml, 100 mg of streptomycin per ml, and 10% fetal
calf serum (FCS), designated DMEM complete, in an incubator
with 5% CO2 at 37uC.
Sera collection, HCV inoculations with serum and HCVcc,
and a-CD81 neutralization
The patient’s blood was collected in VacutainerH Rapid Serum
Tube (Becton Dickinson, Franklin Lakes, NJ) according to
standard hospital techniques and serum was separated after
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kept at 280uC. For inoculation of Huh7.5 with patient sera,
Huh7.5 cells were seeded onto 12-well plates 18 h prior to
inoculation, 8610
4 cells/well. At the day of inoculation sera were
thawed gently at 4uC. DMEM complete was aspirated from cells,
which were washed 36 with PBS. Sera were diluted 1:10 to
DMEM complete without FCS and the DMEM-sera mix was used
to inoculate Huh7.5 cells. Four h post inoculation DMEM-sera
mix was aspirated, cells were washed 36with PBS, and then fed
with DMEM complete with FCS for 96 h. In the case of HCVcc
inoculations, cells were inoculated with cell culture supernatant
derived by RNA (J6/JFH1 or JFH1/DGDD)-electroporated
Huh7.5 cells. For neutralization with a-CD81 antibodies, cells
were incubated with a-CD81 antibodies at a concentration of
2 mg/mL (Clone JS-81, BD Pharmingen
TM, San Diego, CA) for
1 h prior to inoculation with patient sera or HCVcc.
HCV RNA extraction from serum and cloning procedures
Protocols for HCV RNA extraction from serum and cloning
procedures are provided as Materials and Methods S1. Primers’
combinations for the cloning of the BHCV1 and JFH1 viruses are
presented in Table S1 and Table S2, respectively. Sequences of all
primers used in this study are listed in Table S3 (forward primers)
and in Table S4 (reverse primers).
In vitro transcription
Plasmids carrying BHCV1 and JFH1 constructs were linearized
with the XbaI enzyme and plasmid DNA was purified with the
QIAquick PCR purification kit (Qiagen, Du ¨sseldorf, Germany).
Purified DNA was subjected to an in vitro transcription reaction
with the MEGAscriptH T7 kit (Applied Biosystems, Foster city,
CA) according to the manufacturer’s protocol. RNA from the in
vitro transcription reaction was purified with the NucleospinH RNA
II kit (Macherey-Nagel, Du ¨ren, Germany). RNA integrity was
verified by denaturing agarose gel electrophoresis and the
concentration was determined by measurement of the optical
density at 260 nm. Finally, the RNA was stored at 280uC.
Electroporation of HCV RNAs
Single-cell suspensions of Huh7.5 cells were prepared by trypsin-
ization of monolayers and subsequent resuspension was conducted
with DMEM complete. Cells were washed with phosphate-buffered
saline (PBS), counted, and resuspended at 1.5610
7 cells per ml in
Cytomix [41] containing fresh 2 mM ATP and 5 mM glutathione.
Ten mgo fin vitro transcribed RNA was mixed with 400 mlo ft h ec e l l
suspension by pipetting. Cells were then electroporated and
immediately transferred to 10 ml of complete DMEM. Subsequently,
the cells were seeded at a density of 3.125610
5 cells/cm
2,w h i c h
corresponds to 2 ml of the cell suspension per well in a six-well plate.
Electroporation conditions were 960 mFa n d2 7 0Vb yu s i n gaG e n e
Pulser Xcell
TM system (Bio-Rad, Munich, Germany) and a cuvette
with a gap width of 0.4 cm (Bio-Rad).
For the generation of HCVcc stocks (J6/JFH1 virus or JFH1/
DGDD negative control), 10 mL of electroporated cells were
seeded onto 10-cm dishes. Supernatant from the electroporated
cells was harvested 96 h post electroporation, cleared by passing
them through 0.45-mm-pore-size filters. Supernatants were kept at
4uC for up to 3 weeks without significant loss of infectivity, as
determined by TCID50 estimation of the virus titer.
Indirect immunofluorescence
Cells were seeded on glass coverslips in 24-well plates at a
density of 8610
4 per well 24 h before infection, followed by
inoculation with 250 ml of filtered cell culture supernatant
containing JFH1 or J6/JFH1 virus or patient serum diluted 1:10
to DMEM complete without FCS. Four h post inoculation inocula
were removed, cells were washed 36with PBS, and fresh DMEM
complete was added to all of the cells. After 96 h, cells were fixed
with 4% paraformaldehyde in PBS and permeabilized with 0.5%
Triton X-100 in PBS. For electroporated Huh7.5 cells, 250 mlo f
post-electroporation cell suspension were seeded on similar
coverslips and the cells were then cultivated for 72 h. Immuno-
staining of core protein was performed by using the mouse
monoclonal a-core antibody C7-50 (Santa Cruz Biotechnologies,
Santa Cruz, CA) at a final concentration of 1 mg/mL in PBS
supplemented with 5% bovine serum albumin (BSA). Bound
primary antibodies were detected using goat a-mouse antibodies
conjugated to AlexaFluorH 568 (Invitrogen, Eugene, OR) at a
dilution of 1:1000 in PBS with 5% BSA. DNA was stained with
DAPI (49, 6-Diamidino-2-phenylindole dihydrochlorid) (Sigma-
Aldrich, St. Louis, MO). Finally, cells were washed 36with PBS
and once with water and mounted on glass slides with
Fluoromount G (Southern Biotechnology Associates, Birmingham,
AL). For LD staining, post-incubation cells containing the
secondary AlexaFluorH antibody were incubated with 20 mg/mL
BODIPY493/503 (Invitrogen, Eugene, OR) for 10 min, washed 3
timed with PBS, and then counterstained with DAPI.
Preparation of cell lysates, PAGE, and Western blot
analysis
In order to prepare cell lysates, electroporated cells were
harvested by removing the growth medium and were then washed
with PBS. Cells were trypsinized with 0.25% Trypsin-EDTA
solution (Sigma-Aldrich, St. Louis, MO), collected, and centri-
fuged at 1200 rpm for 5 min. The cell pellet was lysed with 1%
Triton X-100 in PBS and clarified by centrifugation at 13000 rpm
for 10 min. Finally, debris-free supernatant was kept at 280uC.
Total protein in the lysates was quantified with a Lowry protein
assay and an equal amount of protein for each sample was diluted
into sample buffer (160 mM Tris, pH 6.7, 2% SDS, 700 mM b-
mercaptoethanol, 10% glycerol, 0.004% bromophenol blue).
Samples were heated at 70uC for 10 min to fully denature
proteins and then loaded onto a 4–12% SDS-polyacrylamide gel
(NuPAGEH, Novex 4–12%, Bis-Tris Midi gels, Invitrogen,
Eugene, OR). Following electrophoresis, proteins were transferred
to polyvinylidine fluoride membrane (PerkinElmer, Life Sciences,
CA). Blots were blocked overnight at 4uC in blocking solution (5%
milk powder and 0.05% Tween 20 in PBS). Incubation with the
primary antibody (a-core C7-50 at a final concentration of 1 mg/
mL or a-b-actin ACTBD11B7 at a final concentration 0,1 mg/
mL; both purchased from Santa Cruz Biotechnologies, Santa
Cruz, CA) was performed in blocking solution for 1 h at room
temperature. Blots were washed five times for 10 min in washing
solution (0.05% Tween 20 in PBS), incubated for 1 h with a-
mouse horseradish peroxidase-conjugated secondary antibody in
blocking solution (1:5000, Sigma-Aldrich, St. Louis, MO), and
washed as described above. Antibody-protein complexes were
detected using the SuperSignalH West Femto Maximum Sensitiv-
ity Substrate Kit (Thermo Fischer Scientific Inc., MA).
Luciferase assays
The Luciferase Assay System (Promega Madison, WI) was used
for the quantification of luciferase reporter activity according to
the manufacturer’s protocol. In brief, electroporated Huh7.5 cells
were resuspended in 10 ml complete DMEM, and 2 ml of the
suspension was seeded per well in a six-well plate for harvesting at
4, 24, 48, 72, and 96 h after transfection (always in duplicates). To
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150 mlo f1 6cell culture luciferase lysis reagent was added. Cells
were frozen immediately, and after having thawed, lysates were
resuspended by pipetting. For each well, 3650 ml lysate was mixed
with 50 ml assay buffer (containing the luciferase substrate)
measured for 5 s in a luminometer (Orion II Microplate
Luminometer, Berthold Detection Systems, Pforzheim, Germany).
Quantification of HCV core protein
HCV core protein in cell culture supernatants was quantified
using the OrthoH HCV antigen ELISA test kit (Ortho Clinical
Diagnostics, Tokyo, Japan). Cell culture supernatants were
harvested at different time points, filtered through 0.45-mm-pore-
size filters and kept at 280uC until the day of measurement.
Depending on the construct and time of harvest, samples were
diluted 1:10 (or higher) and processed for ELISA according to the
manufacturer’s protocol. Colorimetric measurements were per-
formed using a Sunrise colorimeter (Tecan Trading AG,
Switzerland).
RNA quantification by qRT-PCR
Viral RNA was isolated from virus-infected or electroporated
cells using the Nucleo Spin RNAII kit (Macherey-Nagel, Du ¨ren,
Germany) following the manufacturer’s protocol. RNA concen-
tration was determined by measuring the optical density at
260 nm. Twenty-five ng of the total RNA sample was used for
quantitative qRT-PCR analysis with an Abbott m2000rt sequence
detector system (Abbott Laboratories, Abbott Park, IL). HCV-
specific qRT-PCRs were conducted in triplicate with the OneStep
RT-PCR kit (QIAGEN, Hilden, Germany) using the following 59
NTR-specific probe S-292, 59-6-carboxyfluorescein- CCTGA-
TAGGGTGCTTGCGAGTGCC -tetrachloro-6-carboxyfluores-
cein-39; and primers; S-271, 59- GCGAAAGGCCTTGTGG-
TACT-39; and A-337, 59- CACGGTCTACGAGACCTCCC -39
(Biomers, Ulm, Germany). Reactions were performed in three
stages under the following conditions: stage 1, 60 min at 55uC
(reverse transcription); stage 2, 15 min at 95uC (heat inactivation
of reverse transcriptase and activation of Taq polymerase); and
stage 3, 40 cycles of 15 s at 95uC and 1 min 60uC (amplification).
The total volume of the reaction mix was 15 ml, and it contained
the following components: 2.66 mM 6-carboxy-X-rhodamine
(passive reference), 4 mM MgCl2, 0.66 mM deoxynucleoside
triphosphates, 0.266 mM HCV probe, 1 mM of each HCV primer,
and 0.6 ml enzyme mix. The amount of HCV RNA was calculated
by comparing it to serially diluted in vitro transcripts.
Determination of virus titers in cell culture supernatants
Huh7.5 cells were seeded at a concentration of 1.5610
4 cells per
well in a 96-well plate in a total volume of 200 ml complete
DMEM. Twenty-four hours later, serial dilutions of virus
containing supernatant were added (6 wells per dilution.) Three
days later, cells were washed with PBS and fixed for 20 min with
ice-cold methanol at 220uC. After three washes with PBS, NS5A
was detected with a 1:2000 dilution of the a-NS5A antibody 9E10
(kindly provided by C. Rice, The Rockefeller University, NY,
USA) in PBS for 1 h at room temperature, supplemented with 5%
BSA. Cells were washed again three times with PBS and bound
primary antibodies were detected by incubation in PBS-5% BSA
with goat a-mouse IgG-peroxidise conjugated antibody (Sigma-
Aldrich, St. Louis, MO) at 1:400 dilution. After 1 h incubation at
room temperature, cells were washed three times with PBS; the
Vector NovaRED substrate kit (Linaris Biologische Produkte
GmbH, Wertheim, Germany) was used for detection of peroxi-
dase. Virus titres (50% tissue culture infective dose per ml
(TCID50/ml)) were calculated based on the method described by
Spearman and Ka ¨rber.
HCVpp production and infection of Huh7.5 cells
HCV pseudoparticles were generated by cotransfection of 293T
cells with the jetPEI
TM transfection reagent (Polyplus Transfec-
tion
TM, Illkirch, France) with equal amounts of CMV-driven
expression cassette plasmids of the viral gps of the BHCV1
(pcDNA3.1DcE1E2-BHCV1 or mutants) or of the CG1b isolate
(genotype 1b, plasmid kindly provided by Dr. T. Jake Liang) or an
empty vector (no ENV) and the envelope-defective
pNL4.3.Luc.R
2E
2 proviral HIV genome, according to the
manufacturer’s protocols. The supernatants were collected 48 h
post transfection, cleared by passing them through 0.45-mm-pore-
size filters. HIV p24 antigen content was assessed by using the
commercially available p24 EIA – Innotest
TM HIV Antigen mAb
(Innogenetics, Gent, Belgium). Normalized supernatants (equal
amounts of p24) were used to inoculate Huh7.5 cells for 6 h,
seeded 18 h prior to inoculation in 12 well plates, 8610
4 cells/
well. Cells were lysed 72 h post inoculation and luciferase activity
was measured as described above.
Site-directed mutagenesis
Site-directed mutagenesis to E1 or E2 glycoproteins in the
pcDNA3.1DcE1E2-BHCV1 vector were introduced using the
GeneTailor
TM Site-Directed Mutagenesis System (Invitrogen,
Carlsbad, CA) and primers designed according to the manufac-
turer’s protocol.
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extraction from serum and cloning procedures are
provided at this section.
(DOC)
Table S1 Primers combinations for the cloning of the
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